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ABSTRACT The purpose of this study was to perform a multisite evaluation to establish the performance characteristics of the BD Max extended enteric bacterial
panel (xEBP) assay directly from unpreserved or Cary-Blair-preserved stool specimens
for the detection of Yersinia enterocolitica, enterotoxigenic Escherichia coli (ETEC),
Vibrio, and Plesiomonas shigelloides. The study included prospective, retrospective, and prepared contrived specimens from 6 clinical sites. BD Max xEBP results
were compared to the reference method, which included standard culture techniques coupled with alternate PCR and sequencing, except for ETEC, for which the
reference method was two alternate PCRs and sequencing. Alternate PCR was also
used to conﬁrm the historical results for the retrospective specimens and for discrepant result analysis. A total of 2,410 unformed, deidentiﬁed stool specimens were
collected. The prevalence in the prospective samples as deﬁned by the reference
method was 1.2% ETEC, 0.1% Vibrio, 0% Y. enterocolitica, and 0% P. shigelloides.
Compared to the reference method, the positive percent agreement (PPA) (95% conﬁdence interval [CI]), negative percent agreement (NPA) (95% CI), and kappa coefﬁcient (95% CI) for the BD Max xEBP assay for all specimens combined were as follows: ETEC, 97.6% (87.4 to 99.6), 99.8% (99.5 to 99.9), and 0.93 (0.87 to 0.99); Vibrio,
100% (96.4 to 100), 99.7% (99.4 to 99.8), and 0.96 (0.93 to 0.99); Y. enterocolitica,
99.0% (94.8 to 99.8), 99.9% (99.8 to 99.9), and 0.99 (0.98 to 1); P. shigelloides, 100%
(96.4 to 100), 99.8% (99.5 to 99.9), and 0.98 (0.95 to 1), respectively. In this multicenter study, the BD Max xEBP showed a high correlation (kappa, 0.97; 95% CI, 0.95
to 0.98) with the conventional methods for the detection of ETEC, Vibrio, Y. enterocolitica, and P. shigelloides in stool specimens from patients suspected of acute gastroenteritis, enteritis, or colitis.
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D

iarrheal syndrome-based, gastrointestinal (GI) molecular panels are becoming a
popular alternative to traditional microscopy, culture, and antigen detection methods for the detection of enteric pathogens (EPs). These multiplex molecular panels have
the advantage of increased sensitivity with reduced turnaround time and improved
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detection of mixed infections in comparison to traditional methods (1, 2). Ultimately,
this methodology allows for more rapid diagnosis and decisions regarding treatment
and infection control measures.
Two approaches to multiplex syndromic panels have been observed. The ﬁrst
approach is to have a comprehensive panel that covers all potential enteric pathogens,
including bacteria, viruses, and/or parasites and/or Clostridium difﬁcile targets within a
single panel. Examples of these include the BioFire FilmArray gastrointestinal (GI) panel
(BioFire Diagnostics, Inc., Salt Lake City, UT), the Luminex Nanosphere Verigene enteric
pathogen (EP) panel (Luminex Corporation, Toronto, ON, Canada), and the Luminex
xTAG gastrointestinal pathogen panel (GPP). The second approach is to have smaller
molecular panels that target microorganism-speciﬁc groups, i.e., a bacterial panel, a
parasite panel, a viral panel, and a C. difﬁcile assay. The BD Max system (BD Diagnostics,
Sparks, MD, USA) uses the latter for a more targeted approach.
The BD Max system is a fully automated PCR instrument with sample-to-result
capability. In 2014, the BD Max enteric bacterial panel (EBP) for the detection of
Salmonella spp., Shigella spp., Campylobacter jejuni/coli, and Shiga toxin genes (stx1 and
stx2) was U.S. FDA cleared, European CE marked, and Health Canada IVD approved (3).
The panel allowed for the partial transition of a bacterial culture-speciﬁc stool bench to
a less labor-intensive molecular approach. However, the panel did not cover the full
spectrum of enteric bacterial pathogens. Thus, the BD Max extended enteric bacterial
panel (xEBP) was created to be used in conjunction with the BD Max EBP assay as an
optional master mix addition to simultaneously detect Yersinia enterocolitica, enterotoxigenic Escherichia coli (ETEC), Vibrio (Vibrio parahaemolyticus, Vibrio cholerae, and
Vibrio vulniﬁcus), and Plesiomonas shigelloides.
The purpose of this study was to perform a large, multisite evaluation to establish
the performance characteristics of the BD Max xEBP assay for the direct, qualitative
presence of Y. enterocolitica, ETEC, Vibrio, and P. shigelloides directly from unpreserved
or Cary-Blair-preserved stool specimens in comparison to the reference methods.
RESULTS
Demographic data. A total of 2,410 unformed, deidentiﬁed stool specimens were
evaluated, including 2,264 (93.9%) prospective fresh/frozen and 146 retrospective
(6.1%) specimens. The majority (55.9%) of specimens were collected in the outpatient
setting with the remaining 31.0% from the inpatient setting, 9.5% from emergency
departments, and 0.1% from long-term-care facilities. The specimens were evenly
distributed between patients aged ⱕ18 years (42.6%) and ⱖ19 years (56.6%) and
between males (48%) and females (51%). For some specimens, demographic information was unknown.
Prospective specimens. A total of 2,264 prospective specimens including 1,382
(61.0%) Cary-Blair-preserved and 882 (39.0%) unpreserved specimens were collected.
These specimens included 853 (37.7%) prospective fresh specimens and 1,411 (62.3%)
prospective frozen specimens. The results of the BD Max xEBP assay for prospective
fresh and prospective frozen specimens compared to those of culture and ETEC PCRs
(reference method) are summarized in Table 1 for each target. There were no statistically signiﬁcant differences for the positive percent agreement (PPA) and negative
percent agreement (NPA) between prospective fresh and prospective frozen results for
each target (when applicable for PPA), nor were there any statistically signiﬁcant
differences between Cary-Blair-preserved and unpreserved specimens observed (Table
2). The prevalence in the prospective samples as deﬁned by the reference method was
1.2% (26/2,218) ETEC, 0.1% (2/2,250) Vibrio, 0% Y. enterocolitica, and 0% P. shigelloides.
Retrospective specimens. Overall, a total of 146 retrospective specimens were
enrolled and included 59 (40.4%) Cary-Blair-preserved and 87 (59.6%) unpreserved
specimen. The results of the BD Max xEBP assay for retrospective specimens compared
to an alternate PCR and bidirectional sequencing for each target are summarized in
Table 1. Similarly to the prospective specimens, there was no statistically signiﬁcant
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TABLE 1 Performance of the BD Max xEBP by specimen origin
BD Max xEBP performance characteristic compared to the reference methodc,g
No. of specimens with result:
PPA (95% CI)

NPA (95% CI)

Kappaf
(95% CI)

838
1,388
66
384
2,676

No data
100 (32.4–100)
100 (51.0–100)
100 (95.2–100)
100 (96.4–100)

99.9 (99.3–100)
99.6 (99.1–99.8)
98.4 (91.4–99.7)
100 (98.4–100)
99.7 (99.4–99.8)

0.96 (0.93–0.99)

834
1,384
84
287
2,589

834
1,387
92
384
2,697

No data
No data
100 (64.6–100)
100 (96.2–100)
100 (96.4–100)

100 (99.5–100)
99.8 (99.4–99.9)
98.8 (93.6–99.8)
99.7 (98.1–99.9)
99.8 (99.5–99.9)

0.98 (0.95–1)

0
1
0
0
1

823
1,381
79
287
2,570

823
1,382
88
384
2,676

No data
No data
100 (70.1–100)
99.0 (94.3–99.8)
99.0 (94.8–99.8)

100 (99.5–100)
99.9 (99.6–100)
100 (95.4–100)
99.7 (97.8–99.9)
99.96 (99.8–1)

0.99 (0.98–1)

0
4
1
5

821
1,345
54
2,220

830
1,366
70
2,266

100 (70.1–100)
100 (81.6–100)
93.3 (70.2–98.8)
97.6 (87.4–99.6)

100 (99.5–100)
99.7 (99.2–99.9)
98.2 (90.4–99.7)
99.8 (99.5–99.9)

0.93 (0.87–0.99)

Organism and specimen
type
Vibrio
Prospective fresh
Prospective frozen
Retrospectivea
Contrived
Total

True
pos

False
neg

False
pos

True neg

Total

0
2
4
96
102

0
0
0
0
0

1
6
1
0
8

837
1,380
61
288
2,566

Plesiomonas shigelloides
Prospective fresh
Prospective frozen
Retrospectivea
Contrived
Total

0
0
7
96
103

0
0
0
0
0

0
3
1
1d
5

Yersinia enterocolitica
Prospective fresh
Prospective frozen
Retrospectivea
Contrived
Total

0
0
9
95
104

0
0
0
1e
1

ETEC
Prospective fresh
Prospective frozen
Retrospectivea
Total

9
17
14
40

0
0
1
1

b

aResults

of all retrospective samples were conﬁrmed by alternate PCR and bidirectional sequencing prior to testing with the BD Max xEBP.
of specimens varies by target due to differences in compliance with study protocol and unresolved results.
cAbbreviations: pos, positive; neg, negative; PPA, positive percent agreement; NPA, negative percent agreement; CI, conﬁdence interval.
dOne false-positive result occurred initially for P. shigelloides from an unpreserved specimen at 4 times the LoD but was found negative upon repeat testing from the
SBT.
eOne false-negative result was observed for Y. enterocolitica among a Cary-Blair-preserved specimen at 4 times the LoD but was positive upon repeat testing from the
SBT.
fKappa coefﬁcient, correlation of BD Max result with reference methods.
gReference methods were standard culture techniques and/or alternate PCR followed by sequencing.
bNumber

difference for the PPA and NPA between Cary-Blair-preserved and unpreserved specimens (Table 2).
Contrived specimens. The contrived specimen results for Y. enterocolitica, Vibrio,
and P. shigelloides are summarized in Table 1 and further divided by specimen type
(Cary-Blair versus unpreserved) in Table 2. Two discrepant results were observed. One
false-positive result occurred initially for P. shigelloides from an unpreserved specimen
at 4 times the limit of detection (LoD) but was found negative upon repeat testing from
the sample buffer tube (SBT). One false-negative result was observed for Y. enterocolitica among a Cary-Blair-preserved specimen at 4 times the LoD but was positive upon
repeat testing from the SBT.
Discrepant results. Discrepant results are summarized in Table 3. Overall, 19 (0.8%)
discrepant results were observed including 8 (42.1%) Vibrio results, 6 (31.6%) ETEC
results, 4 (21.1%) P. shigelloides results, and 1 (5.3%) Y. enterocolitica result. Overall,
18/19 (94.7%) were false-positive (FP) results with threshold cycle (CT) values greater
than 32 (except 3 positive Vibrio results with CT values of 20.9, 22.2, and 31.9; CT values
are not available to the end user). A single false-negative (FN) result occurred for a
retrospective unpreserved specimen positive for ETEC. Discrepant results occurred in
both prospective and retrospective specimens and among both Cary-Blair-preserved
and unpreserved specimens. Three discrepant retrospective results were not available
for discrepant analysis due to limited specimen volume (one ETEC FN, one ETEC FP, and
one Vibrio FP). Of the 16 FP discrepant specimens tested by discrepant analyses, there
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TABLE 2 Performance of the BD Max xEBP by specimen type
BD Max xEBP performance characteristics compared to the
reference methodb,f
No. of specimens with result:
Organism and specimen
type
Vibrio
Clinical specimensc
Cary-Blair preserved
Unpreserved
Contrived specimens
Cary-Blair preserved
Unpreserved
Total
Plesiomonas shigelloides
Clinical specimensc
Cary-Blair preserved
Unpreserved
Contrived specimens
Cary-Blair preserved
Unpreserved
Total

True False False True
pos neg pos neg

Totala PPA (95% CI)

NPA (95% CI)

4
2

0
0

5
3

1,367 1,376
911
916

100 (51–100)
100 (34.2–100)

99.6 (99.1–99.8)
99.7 (99–99.9)

48
48
102

0
0
0

0
0
8

144
192
144
192
2,566 2,676

100 (92.6–100)
100 (92.6–100)
100 (95.4–100)

100 (97.4–100)
100 (97.4–100)
99.7 (99.4–99.9)

4
3

0
0

2
2

1,393 1,399
909
914

100 (51–100)
100 (43.9–100)

99.9 (99.5–100)
99.8 (99.2–99.9)

48
48
103

0
0
0

0
1d
5

144
192
143
192
2,589 2,697

100 (92.6–100)
100 (92.6–100)
100 (95.5–100)

100 (97.4–100)
99.3 (96.2–99.9)
99.8 (99.5–99.9)

99.9 (99.6–100)
100 (99.6–100)

Yersinia enterocolitica
Clinical specimensc
Cary-Blair preserved
Unpreserved
Contrived specimens
Cary-Blair preserved
Unpreserved
Total

0
9

0
0

1
0

1,373 1,374
910
919

No data
100 (70.1–100)

47
48
104

1e
0
1

0
0
1

144
192
144
192
2,570 2,676

97.9 (89.1–99.6) 100 (97.4–100)
100 (92.6–100) 100 (97.4–100)
99.0 (94.0–99.9) 99.9 (99.7–99.9)

ETEC (clinical
specimensc)
Cary-Blair preserved
Unpreserved
Total

15
25
40

0
1
1

3
2
5

1,376 1,394
844
872
2,220 2,266

100 (79.6–100) 99.8 (99.4–99.9)
96.2 (81.1–99.3) 99.8 (99.1–99.9)
97.6 (85.6–99.9) 99.8 (99.4–99.9)

aNumber

of specimens varies by target due to differences in compliance with protocol and unresolved
results.
bAbbreviations: pos, positive; neg, negative; PPA, positive percent agreement; NPA, negative percent
agreement; CI, conﬁdence interval.
cClinical specimens include the prospective fresh, prospective frozen, and retrospective specimens.
dThe sample was initially positive for P. shigelloides but was negative on repeat testing from the SBT.
eThe sample was initially negative for Y. enterocolitica but was positive on repeat testing from the SBT.
fReference methods were standard culture techniques and/or alternate PCR followed by sequencing.

were 7 Vibrio, 4 P. shigelloides, 4 ETEC, and 1 Y. enterocolitica result. Three of 4 FP P.
shigelloides results were also positive for a second target on the BD Max (1 ETEC, 1 Y.
enterocolitica, and 1 Vibrio).
Unresolved results. Unresolved results due to failure of the internal control could
be caused by inhibitory substances in the stool specimens or reagent or instrument
failure. For Cary-Blair-preserved specimens, the unresolved rate was 2.4%, and for
unpreserved specimens, the unresolved rate was 2.2%. After repeat testing, the unresolved rate fell below 0.3% for both specimen types.
DISCUSSION
The fully automated BD Max system takes a microorganism group-speciﬁc approach
to the detection of gastrointestinal pathogens. Currently, there are four panels that are
FDA cleared for the BD Max system: a C. difﬁcile toxin B gene assay, an enteric bacterial
panel (EBP), an enteric parasite panel (EPP), and last, the most recent panel to receive
FDA clearance, the extended EBP (xEBP) that was evaluated in this multicenter study (3,
4). To cover the full spectrum of enteric pathogens on the BD Max system, an enteric
November 2017 Volume 55 Issue 11
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TABLE 3 BD Max discrepant results for prospective and retrospective specimens
Target
Vibrio

No. (%) of discrepant
Type of
results (n ⴝ 19)
Specimen originb Specimen type
discrepancy
8 (42.1)
7 prospective, 1
5 Cary-Blair preserved, False positive
retrospective
3 unpreserved

Plesiomonas shigelloides 4 (21.1)

3 prospective, 1
retrospective

Yersinia enterocolitica

1 (5.3)

1 prospective

ETEC

6 (31.6)

4 prospective, 2
retrospective

Discrepant analysis resulta
5/8 were negative by both xEBP
and alternate PCR, 2/8 were
repeat positive by the xEBP
and negative by alternate
PCR, 1/8 was unavailable for
retesting
2 Cary-Blair preserved, False positive
1/4 was negative by both xEBP
2 unpreserved
and alternate PCR, 3/4 were
repeat positive by the xEBP
and negative by alternate
PCR
1 Cary-Blair preserved False positive
1/1 was negative by both xEBP
and alternate PCR
3 Cary-Blair preserved, 5 false positive, 1 1/6 was negative by both xEBP
3 unpreserved
false negative
and alternate PCR, 1/6 was
repeat positive by the xEBP
and negative by alternate
PCR, 2/6 were repeat positive
by the xEBP and positive by
alternate PCR and
sequencing, 2/6 were
unavailable for retesting

aDiscrepant

analysis included repeat testing on the xEBP assay and an alternate PCR followed by bidirectional sequencing.
discrepant retrospective results were not available for discrepant analysis due to limited specimen volume (one ETEC false negative, one ETEC false positive,
and one Vibrio false positive).

bThree

virus panel (EVP) is currently undergoing FDA clinical trials and should be available
soon.
Syndrome-based GI panels cast a broad net for clinically indistinguishable diseases
to ultimately help achieve a more timely diagnosis. One study evaluating the xTAG GPP
assay found that physician ordering practices missed up to 65% of pathogens detected
by the panel (5). However, some argue that these comprehensive panels should be
restricted for use in only certain patient populations such as the critically ill, immunocompromised hosts, patients with a travel history, and patients with prolonged diarrhea
(1, 3). The BD Max microorganism group-speciﬁc panel-based method provides a happy
medium between the comprehensive panels and traditional techniques. The BD Max
panels allow for a tailored approach to GI pathogen test ordering and detection,
enabling clinicians to order based on the patient’s risk factors, such as communityacquired versus hospital-acquired diarrhea, an immunocompetent versus immunocompromised host, and/or pediatric versus adult patients (6). Furthermore, the expense of
smaller, focused panels is lower than that of broad, comprehensive panels, and thus,
the costs are more likely to be reimbursed by insurance companies (1).
The BD Max xEBP evaluated in this study was designed to be used in conjunction
with the BD Max EBP assay as an optional master mix addition to simultaneously detect
Y. enterocolitica, ETEC, Vibrio, and P. shigelloides. The addition of the xEBP master mix to
the EBP allows for the complete transition of a bacterial culture-speciﬁc stool bench to
a less labor-intensive molecular approach (7). That being said, there is one bacterial
enteric pathogen not included in the panels—Aeromonas species. Thus, laboratories
that convert completely to a molecular biology-based approach using the BD Max
system for the detection of bacterial enteric pathogens must decide if they are still
going to offer Aeromonas species culture, as Aeromonas is known to be an enteric
pathogen in both pediatric and adult populations (8, 9). However, the detection of
Aeromonas in fecal specimens should be interpreted with caution as it may not always
be associated with disease and has been found among healthy patient controls (10, 11).
One additional disadvantage of moving to a molecular biology-based approach is
increased laboratory expenses. However, these expenses might be overcome by deNovember 2017 Volume 55 Issue 11
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creasing technologist hands-on time (2) or by net cost savings for the hospital by
shortening patient isolation days due to more rapid results than conventional methods,
as demonstrated in a recent study (12).
The prevalences of ETEC, Vibrio, Y. enterocolitica, and P. shigelloides in the prospective samples were 1.2%, 0.1%, 0%, and 0%, respectively. Although it is well documented
that these pathogens are less likely to be encountered (with the exception of ETEC), the
prevalences of Y. enterocolitica and P. shigelloides in this multicenter study were
surprisingly low. These observations are similar, however, to a recent multicenter trial
evaluating the FilmArray GI panel in the United States that found the prevalence of
ETEC, P. shigelloides, Vibrio, and Y. enterocolitica to be 1.4% (22/1,556), 0.2% (3/1,556),
0% (0/1,556), and 0.1% (1/1,556), respectively (13). Seasonality was considered an
explanation for the low prevalence of targets; however, study enrollment spanned a
calendar year and removed this as a variable. Our result for ETEC was also consistent
with that of a recent U.S. study describing a prevalence of 1% (5). Interestingly, ETEC
was the sixth most commonly encountered GI pathogen in two recent studies
evaluating multiplex molecular GI panels from the United States (1%) and Europe
(4.23%) (6, 14).
Due to the low prevalence of pathogens in the prospective arm (with the exception
of ETEC), both retrospective and contrived samples were included in the study. Compared to the reference method, the positive percent agreement, negative percent
agreement, and kappa coefﬁcient for the BD Max xEBP assay for all specimens combined and for all targets were ⱖ97.6%, ⱖ99.7%, and 0.97, respectively. These results are
similar to those reported by the multicenter clinical trial for the FilmArray gastrointestinal panel (13). In contrast, a multicenter study evaluating the xTAG GPP demonstrated
a sensitivity of 0% (0/2 specimens) for detection of Yersinia enterocolitica and was not
able to assess the sensitivity for ETEC and V. cholerae due to the lack of positive
specimens (5). A subsequent study, comparing the FilmArray GI panel to the xTAG GPP,
further conﬁrmed the poor sensitivity of the xTAG GPP for the detection of Yersinia
enterocolitica, detecting less than half of previously positive stool samples (13/27;
48.1%) which were all detected by the FilmArray GI panel (14). Overall, the sensitivity
of these multiplex panels for the detection of the enteric organisms covered by the
xEBP assay from prospective stool specimens has not been well deﬁned due to the low
prevalence of these pathogens in developed countries.
Nineteen (0.8%) discrepant results were observed in this study, of which the majority
(18/19) were false-positive results and mostly occurred in prospective frozen samples
(16/18). Two of the false-positive ETEC results were conﬁrmed by discordant analysis.
The remainder were not conﬁrmed by alternate PCR. Despite these false-positive
results, the speciﬁcities for these targets were ⱖ99.7% in the prospective cohort. These
false-positive results could be due to cross-reactivity of primers and probes with other
off-panel targets. For example, a few false-positive results for ETEC by the FilmArray
study were attributed to cross-reactivity with Citrobacter koseri and Hafnia alvei in the
specimens (13). However, analytical speciﬁcity studies revealed that of 184 organisms
tested for cross-reactivity, only two strains of Vibrio mimicus were found to cross-react
with the Vibrio target on the xEBP assay (data not presented). Laboratory contamination
is another possible cause of the false-positive results, even though environmental
testing was performed at each site to assess and control contamination weekly during
testing. Finally, the limit of detection of the BD Max assay could potentially be lower
than those of the reference and discrepant analysis methods. As with all diagnostic
assays, positive predictive value is a function of the disease prevalence; therefore, when
the prevalence is low, the predictive value is expected to be lower. Therefore, in
settings where disease prevalence is very low, laboratories may consider the possibility
of repeat testing or conﬁrmation of the test result by another method.
The unresolved rates among preserved (2.4%) and unpreserved (2.2%) specimens in
this study were similar. This is in contrast to what was observed in the BD Max EBP
multisite evaluation, where there was a higher unresolved rate among unpreserved
specimens (7.1% compared to 3.7% for preserved specimens). It was thought that
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dilution of the stool in Cary-Blair medium reduced the effects of inhibitory substances
(3). No changes in the extraction or internal controls were made between the EBP and
xEBP assays to account for the lower unresolved rates between the two specimen types.
However, changes were made to the pipetting/mixing protocol on the BD Max system
that have signiﬁcantly reduced the occurrence of bubbles in the PCR cartridge, consequently reducing the unresolved rate.
A limitation of this study is the low number of positives for Vibrio, Y. enterocolitica,
and P. shigelloides in the prospectively collected cohort, requiring the use of both
retrospective and contrived specimens to determine the sensitivity for detection of
these targets. Strengths of this study include the multicenter analysis including sites in
the United States and Canada, the large number of stool specimens enrolled, and the
inclusion of both Cary-Blair-preserved and unpreserved specimens.
In conclusion, in this large, multicenter study, the BD Max xEBP showed a very high
correlation with conventional and molecular methods for the detection of ETEC, Vibrio,
Y. enterocolitica, and P. shigelloides in stool specimens of patients suspected of or
having acute gastroenteritis, enteritis, or colitis.
MATERIALS AND METHODS
Study design and specimen types. The study was conducted between June 2015 and May 2016
and included 6 clinical sites. Five sites were located in the United States, and one was in Canada. Overall,
2,410 unformed, deidentiﬁed stool specimens were obtained from unique pediatric or adult patients
suspected of or having acute gastroenteritis, enteritis, or colitis. Acceptable specimens included unpreserved stool specimens and Cary-Blair-preserved stool specimens. This study included prospectively
collected fresh specimens (prospective fresh) as well as specimens collected earlier in the season (June
to December 2015) and frozen (ⱕ⫺70°C) prior to testing on the BD Max system (prospective frozen). The
prospective frozen specimens were tested at the clinical trial sites within the stability period as
established by the manufacturer for the xEBP assay (9 months) and reference methods (9 to 10 months
depending on the target). The vast majority of these specimens were remnant specimens from patients
suspected of acute gastroenteritis, enteritis, or colitis. For one site, three stool specimens were also
collected under informed consent for the purpose of this study. Considering the low prevalence of the
assay targets, retrospectively archived specimens (including specimens from one site in Uganda) and a
contrived specimen study were included to supplement the number of positives.
Contrived specimens. The contrived specimen study was performed to supplement the number of
positive results for Y. enterocolitica (12 strains), Vibrio (V. parahaemolyticus, V. vulniﬁcus, and V. cholerae;
4 strains each of 3 species), and P. shigelloides (12 strains), for both unpreserved and Cary-Blair-preserved
stools (15). Overall, a total of 384 contrived samples were tested, 128 at each of three testing sites. Each
strain was tested at 2 times, 4 times, 5 to 10 times, 15 to 25 times, and 500 to 1,000 times the limit of
detection (LoD). For information on the LoD for each target, we refer readers to the BD Max xEBP package
insert (15).
Reference methods for prospective specimens. The prospective specimens were cultured within
96 h of collection for Cary-Blair-preserved specimens and 24 h for unpreserved specimens. Clinical and
Laboratory Improvement Amendment (CLIA)-compliant culture methods for standard patient care were
used at each site, and appropriate quality control was documented according to the Clinical and
Laboratory Standards Institute (CLSI) M22-A3 guidelines. Each site had to pass a culture proﬁciency panel
prior to culture enrollment. Stools were cultured directly using cefsulodin (15 mg)-Irgasan-novobiocin
(CIN; BD BBL prepared medium; Sparks, MD), thiosulfate-citrate-bile salts-sucrose agar (TCBS; BD BBL
prepared medium), and Trypticase soy agar with 5% sheep blood (blood agar; BD BBL prepared medium).
Culture combined with standard identiﬁcation laboratory practice (visual inspection and oxidase testing)
was used for Y. enterocolitica, the Vibrio group, and P. shigelloides. An additional characterization (e.g.,
validated alternate PCR and bidirectional sequencing) was also performed on all presumptive positive
isolates. For ETEC, the xEBP results were compared to two sets of validated alternate PCRs (a total of six
PCRs for three toxins) performed directly from the stool, followed by bidirectional sequencing of the
amplicon from PCR set 1 only. Heat-labile toxin (LT), heat-stable porcine-type variant toxin (STp), and
heat-stable human-type variant toxin (STh) were the three toxins detected. The same proprietary
alternate PCRs that were used to conﬁrm prospective results were also used to conﬁrm the presence of
targets in the retrospective specimens and to assess discrepant results, as described below.
Reference method for retrospective specimens. Historical results obtained from standard routine
methods were used as the ﬁrst portion of a composite reference method. In addition, all specimens
underwent testing with one alternate PCR (one set of PCRs for ETEC with one PCR for each toxin type)
followed by a bidirectional sequencing method to conﬁrm historical routine testing results as targets
may have degraded during storage (4). Only specimens with at least 1 ml of remaining volume for which
historical results had been conﬁrmed with the alternate PCR and bidirectional sequencing were included
in the retrospective study.
BD Max testing. Prospective fresh specimens were tested within 120 h of collection if stored at 4°C
and 48 h if kept at room temperature. The prospective frozen specimens were tested within 9 months
from collection. When thawed, prospective frozen and retrospective specimens were tested within the
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FIG 1 The unitized reagent strip for the BD Max EBP and xEBP assays. The xEBP master mix is added to
the unitized reagent strip of the EBP assay. The setup of the xEBP assay is identical to that of the
FDA-cleared BD Max EBP assay with the exception of adding the additional xEBP master mix tube to the
four-snap EBP unitized reagent strip.

same time frame as those required for prospective fresh specimens as described above. Each site was
required to pass a BD Max xEBP proﬁciency panel prior to testing specimens on the BD Max system. The
BD Max xEBP assay was performed according to the investigational-use-only (IUO) package insert. The
setup of the xEBP assay is identical to that of the FDA-cleared BD Max EBP assay with the exception of
adding the additional xEBP master mix tube to the four-snap EBP unitized reagent strip (URS) (Fig. 1).
Brieﬂy, 10 l of homogenized stool specimen was transferred each into a sample buffer tube (SBT) by use
of a calibrated loop and vortexed. Then, the URS was placed onto a BD Max rack along with the
extraction tubes and the EBP and xEBP master mix tubes by simply snapping them into the individual
URS for each specimen. Last, the SBTs were loaded on the BD Max rack with the URS and reagents and
the rack was placed onto the BD Max system. The BD Max system automates the extraction, real-time
TaqMan-based PCR ampliﬁcation, ﬂuorophore-labeled probe detection, and automatic result interpretation at each PCR cycle. Proprietary targets and primers included in the BD Max xEBP assay detect Y.
enterocolitica, Vibrio (V. cholerae, V. vulniﬁcus, and V. parahaemolyticus), and P. shigelloides. Vibrio is
reported as a composite positive result and does not differentiate among the three species. In addition,
primers and probes detect three toxins produced by ETEC including the heat-labile toxin (LT), the
heat-stable porcine-type variant toxin (STp), and the heat-stable human-type variant toxin (STh). Only
one of the toxin genes needs to be present to be considered a positive result for ETEC. The total run time
for the EBP and xEBP assays together on a single URS is 3.5 h for a batch of 24 samples.
Environmental testing. Environmental testing was performed prior to the start of the BD Max
testing and then regularly until the study concluded; the work area and equipment were monitored for
the presence of target DNA contamination. Environmental swab samples were collected and tested with
the BD Max EBP and xEBP assays. If contamination occurred, the work area and surfaces were properly
decontaminated prior to further specimen testing.
BD Max controls and unresolved results. A positive and negative external control were included
with each run. The positive control was cycled on a daily basis and contained 1.5 ⫻ 105 CFU/ml of ATCC
9610 Y. enterocolitica, ATCC 14033 V. cholerae, ATCC 35401 ETEC, or ATCC 14029 P. shigelloides spiked in
at 5 times the LoD (15). An internal control was included in each extraction tube to monitor extraction,
ampliﬁcation, and detection steps. If results were not reportable due to lack of ampliﬁcation of the
internal control or either of the external controls, the test was repeated using the initially inoculated SBT
within 5 days of inoculation. If the controls failed on repeat, a second SBT was prepared and up to 2
additional extraction and ampliﬁcation reactions could be performed.
Data analysis. Results obtained from the BD Max xEBP assay for the prospective and retrospective
specimens were compared to those obtained with the reference methods as described above. Results
obtained for the contrived specimens were tested by the BD Max xEBP assay and compared to the
expected results. The positive percent agreement (PPA) and negative percent agreement (NPA) were
calculated with 95% conﬁdence intervals. Prevalence rates for each target were calculated as the number
of prospective specimens that tested positive by the reference method divided by the total number of
compliant trial specimens.
Discrepant analysis. Prospective samples with discrepant results between the reference method
and the BD Max xEBP assay were retested by the BD Max xEBP and by an alternate PCR directly from the
stool followed by bidirectional sequencing of the amplicon. The alternate PCRs used distinct targets for
identiﬁcation of the organisms and targeted different regions of the toxin genes for ETEC than did the
BD Max xEBP assay.
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